Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/012409

International filing date: 14 April 2005 (14.04.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
                               Number: 60/561,919
                               Filing date: 14 April 2004 (14.04.2004)

Date of receipt at the International Bureau: 30 May 2005 (30.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

1316960

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

May 19, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: *60/561,919*
FILING DATE: *April 14, 2004*
RELATED PCT APPLICATION NUMBER: *PCT/US05/12409*

Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PROVISIONAL APPLICATION FOR PATENT COVER SHEET
This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Felicia	Etzkorn	Blacksburg, Virginia
Xiadong	Wang	Blacksburg, Virginia
Matthew	Shoulders	Blacksburg, Virginia

☐ *Additional inventors are being named on the ____ separately numbered sheets attached hereto*

TITLE OF THE INVENTION (500 characters max)

COLLAGEN MIMETIC BIOMATERIALS

CORRESPONDENCE ADDRESS

Direct all correspondence to:

☒ Customer Number | **30743**

30743
PATENT TRADEMARK OFFICE

OR

☒ Firm *or* Individual Name | **Whitham, Curtis & Christofferson**

Address	11491 Sunset Hills Road				
Address	Suite 340				
City	Reston	State	Virginia	ZIP	20190
Country	USA	Telephone	703-787-9400	Fax	703-787-7557

ENCLOSED APPLICATION PARTS *(check all that apply)*

☒ Specification *Number of Pages* **9**   ☐ CD(s), Number

☐ Drawing(s) *Number of Sheets*   ☐ Other (specify)

☐ Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☒ Applicant claims small entity status. See 37 CFR 1.27.

☒ A check or money order is enclosed to cover the filing fees

☒ The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number **50-2041**

☐ Payment by credit card. Form PTO-2038 is attached.

FILING FEE AMOUNT ($)
$80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted, [signature]

SIGNATURE _____

TYPED or PRINTED NAME   Michael E. Whitham

TELEPHONE   703-787-9400

Date **4/14/4**

REGISTRATION NO. **32,635**
(if appropriate)
Docket Number: **01640460pr**

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Collagen Mimetic Biomaterials

Felicia A. Etzkorn, Xiaodong J. Wang, Matthew D. Shoulders

Field of Invention

This invention relates to the design and synthesis of collagen-like materials. More particularly the invention relates to materials that mimic the biological structure and behavior of collagen, yet are resistant to degradation.

Summary of the Related Art

Collagen is a highly abundant fibrous protein present throughout the human body, constituting approximately 25% of all protein in the body. Collagen is the scaffolding material found in skin, bones, tendons, cartilage, blood vessels and nearly all organs where it serves to form a matrix for holding and supporting cells. Collagen contains three polyproline type II helix chains each coiling in a left handed manner and coiling with each other to form a right-handed super helix. [1] The unique triple helical structure of collagen results from its primary structure, which can be represented as $(Xaa-Yaa-Zaa)_{300}$, where 10 percent of Xaa is proline, 10-12 percent of Yaa is 4(R)-hydroxyproline, and Zaa is typically Gly. [2,3] The presence of Gly at every third amino acid position is one of the most important structural elements of the collagen triple helix, as Gly is the only amino acid small enough to fit into the highly compacted super helix at that position. However, the high occurrence of hydroxyproline and proline in collagen and interchain hydrogen bonds between C=O and N-H groups contribute to stabilization of collagen's unique triple helical structure. [2,3] A typical molecule of collagen consists of around 300 units of Xaa-Yaa-Gly. This highly repeated sequence of collagen makes possible the polymerization of tripeptide monomers to prepare collagen analogues.

The existence of stable Xaa-Pro and Xaa-Hyp cis and trans amide conformational isomers leads to a significant challenge for folding collagen peptides. [4-8] In native collagens, globular C-terminal domains initiate triple helix formation, [9] but proline isomerization is still the slow step in collagen folding. [10] In an average 300 unit repeat of Xaa-Yaa-Gly, there are thus 600 amides that can exist in cis or trans. The number of possible conformational states of one strand is thus 2^{600}, and this does not include the necessity of triple helix formation. Folding of collagen occurs in a processive fashion. Once the triple helix is formed, the trans conformation is stable within the folded helix. Thus proline isomerization is rate limiting in collagen folding. [4-8]

Significant research has been performed regarding both the unique structural features of collagen and its potential biomedical applications. [11] Collagen is generally regarded as one of the most useful biomaterials due to its excellent biocompatibility and safety. Major uses of collagen as a biomaterial include applications of collagen in drug delivery systems and in tissue-engineering systems. However, the insufficient supply, poor mechanical strength, and ineffectiveness in the management of infected sites of collagen-based systems make improvements necessary. [12]

Several researchers have studied mimics of biological collagen, including polypeptides of the type $(Pro-Pro-Gly)_n$ and $(Pro-Flp-Gly)_n$ (where Flp represents 4(R)-fluoroproline), and all D-amino acid peptides. [13-15] However, none have prepared collagen mimics in which the amide bonds themselves have been altered.

The present invention is aimed towards preparation of self-assembling, biologically stable mimics of collagen via amide bond polymerization of appropriate monomers.

Disclosure of the Invention

The present invention relates to compounds with the general formula (**1A-3**, and Figure 1) which possess properties mimicking that of biological collagen and therefore have potential biomaterials applications.

(Gly-Ψ[*(E)*CH=C]-Xaa-Yaa)$_n$	(**1A**)
(Gly-Xaa-Ψ[*(E)*CH=C]-Yaa)$_n$	(**1B**)
(Gly-Xaa-Yaa-Ψ[*(E)*CH=CH])$_n$	(**1C**)
(Gly-Ψ[*(E)*CH=C]-Xaa-Ψ[*(E)*CH=C]-Yaa)$_n$	(**2A**)
(Gly-Xaa-Ψ[*(E)*CH=C]-Yaa-Ψ[*(E)*CH=CH])$_n$	(**2B**)
(Gly-Ψ[*(E)*CH=C]-Xaa-Yaa-Ψ[*(E)*CH=CH])$_n$	(**2C**)
(Gly-Ψ[*(E)*CH=C]-Xaa-Ψ[*(E)*CH=C]-Yaa-Ψ[*(E)*CH=CH])$_n$	(**3**)

The invention disclosure relates to the case **1A** where Xaa is Pro and Yaa is Hyp. However the scope of the invention includes the general case where any of the 20 natural amino acids are in the Xaa and Yaa positions or where Xaa and Yaa are represented by Hyp or Flp. These materials include block copolymers of alkene isostere monomers with tripeptide monomers, Figure 2. The enantiomeric case where all amino acids and their replacements have the unnatural D-amino acid, *R*- or *S*-stereochemistry at the α-position are also claimed (Figure 2). Such all D-amino acid analogues may have particular stability towards biological degradation with the enantiomeric right-handed triple helix supercoil producing similar macroscopic materials properties, yet interesting alternative biological properties. [15]


**Figure 1.** Structures of polymeric materials claimed.

example block copolymer with **1A**

Figure 2. Block copolymers of peptidomimetic with natural peptides.

Figure 3. Enantiomeric collagen mimic materials claimed.

The structure of the specific monomer prepared is shown in Figure 4. This monomer may be polymerized via amide bond polymerization to form the desired collagen mimic.

Figure 4. Structure of the monomer synthesized for the collagen mimic.

We will synthesize collagen-like peptides via polymerization of the monomer [Gly-Ψ[(E)CH=C]-Pro-Hyp]. Because all the Gly-Pro amide bonds in collagen exist in the trans conformation,[7,8] a route that affords the E monomer stereoselectively is desired. Our recent success in Ser-*trans*-Pro (E)-alkene isostere synthesis provides a route to this Gly-Ψ[(E)CH=C]-Pro-Hyp monomer. [16] Alkene amide bond surrogates provide not only conformational control but also resistance to peptidases. The alkene isostere material is also likely to inhibit collagenase (matrix metalloproteases), and may represent a method for preventing mucositis in cancer therapy,[17] or improving clinical markers of rheumatoid arthritis. [18] These synthetic collagen mimics will contribute not only to studies on the stability of collagen-like triple helical structures but will also provide useful structural biomaterials.

Synthesis of the [Gly-Pro-Ψ[(E)CH=C]Hyp]ₙ Monomer

The synthetic scheme for preparation of the Gly-Ψ[(E)CH=C]Pro amide bond isostere is shown in Scheme 1 analogous to our previously described synthetic scheme. [16]

Scheme 1

The general synthetic scheme displayed in Scheme 1 is applicable to all of the amino acids relevant to this invention as claimed above. In order to obtain a pure enantiomer of 9, we will use a chiral hydrogenation catalyst instead of CeCl₃ in the reduction of α,β-unsaturated ketone 5. We have used binaphthyl rhodium hydrogenation catalyst, but other catalysts are possible. After preparation of 9, the monomer used for the amide bond polymerization may be prepared as displayed in Scheme 2.

Scheme 2

1) TFA, HSiEt₃, DCM → 1) TFA, HSiEt$_3$, DCM

2) TBSCl, imidazole
DMF, two steps 68%

9 → **10**

THF, MeOH, H2O
KOH, 65.3%

11 → **12**

pyBOP, HOBt
polymerization

TBAF/ H$_2$O

1a

The synthesis of the monomer to make material **2B** is shown in Scheme 3. Polymerization can be performed by the method shown in Scheme 2.

Scheme 3

·HCl, DCC,
HOBt, DIEA

DMAP, CH$_2$Cl$_2$, rt

, s-BuLi

iPrMgCl, THF

CeCl$_3$, NaBH$_4$

THF/MeOH

ClCH$_2$OTBS

pyridine, THF, rt

1) LDA, pyridine
TMSCl, THF

2) Bu$_4$N$^+$F$^-$, THF

1) Pb(OAc)$_4$,
CHCl$_3$, EtOAc

2) CrO$_3$, H$_2$SO$_4$
acetone

H$_2$N⌒COOMe

DCC, HOBt

1) NaOH(aq)
THF

2) TFA, CH$_2$Cl$_2$

Synthesis of materials of type C, including **3**, will be polymerized by ADMET (acyclic diene metathesis) catalysis. [19] An example is shown in Scheme 4 for type **1C**.

Scheme 4

metathesis catalysts: Grubb's, Mol's, etc

Experimental

General. Unless otherwise indicated, all reactions were carried out under N_2 in flame-dried glassware. THF and CH_2Cl_2 were dried by passage through aluminum. Anhydrous (99.8%) peptide synthesis grade DMF, NMP and diisopropylethylamine (DIEA) were purchased from Fluka Chemical Co. for solid phase synthesis. Brine (NaCl), $NaHCO_3$, and NH_4Cl refer to saturated aqueous solutions unless otherwise noted. Flash chromatography was performed on 32-63 μm or 230-400 mesh, ASTM silica gel with reagent grade solvents. NMR spectra were obtained at ambient temperature in $CDCl_3$ unless otherwise noted. Proton and carbon-13 NMR spectra were obtained at 500 and 125 MHz, respectively. Coupling constants J are given in Hertz.

Boc-Gly Weinreb amide (4)[20] N-Boc-Gly-OH (10.5 g, 60.0 mmol), N,O-dimethylhydroxylamine hydrochloride (11.1 g, 120 mmol) and DIEA (31.2 g, 240 mmol) were dissolved in 1:1 CH_2Cl_2/DMF (500 mL) and cooled to 0 °C. 1-Hydroxy-1H-benzotriazole (HOBt, 11.0 g, 72.0 mmol), DCC (14.9 g, 72.0 mmol) and DMAP (ca. 100 mg) were added and the reaction was stirred for 24 h. The reaction was filtered to remove dicyclohexylurea and concentrated. The resulting slurry was diluted with 500 mL ethyl acetate and washed with NH_4Cl (2 × 100 mL), $NaHCO_3$ (2 × 100 mL) and brine (100 mL). The organic layer was dried on $MgSO_4$ and concentrated. Chromatography on silica with 20% EtOAc in hexane gave 12.6 g (96%) of **4** as a colorless plate-like crystal. m.p. 101-102 °C. ^{1}H NMR δ 5.25 (br, s, 1H), 4.07 (d, J=3.7, 2H), 3.70 (s, 3H), 3.19 (s, 3H), 1.44 (s, 9H).

Ketone (5). To a solution of 1-iodocyclopentene[16] (2.91 g, 15.0 mmol) in 80 mL THF at -40 °C was added s-BuLi (1.3 M in cyclohexane, 23 ml, 30 mmol). The reaction was stirred at -40 °C for 3 h to generate cyclopentenyl lithium. In another flask, Boc-glycine Weinreb amide **4** (2.18 g, 10.0 mmol) was dissolved in 20 mL of dry THF, degassed and inerted under N_2. The solution was cooled to -15 to -10°C and to the resulting slurry was charged 4.9 mL of 2.0 M i-PrMgCl/THF (9.8 mmol) dropwise at -15 to -5°C to afford a clear solution. After cooling to -78°C, the cyclopentenyl lithium solution was added via cannula to the deprotonated Weinreb amide solution. The mixture was stirred for 1 h at –78 °C, quenched with NH_4Cl (10 mL), diluted with EtOAc (100 mL), washed with NH_4Cl (2 × 20 mL), $NaHCO_3$ (20 ml), brine (20 mL), dried over $MgSO_4$ and concentrated. Chromatography on silica with 10% EtOAc in hexane gave 1.40 g (62%) of ketone **5** as a yellowish solid. ^{1}H NMR δ 6.81 (s, 1H), 5.36 (br, s, 1H), 4.29 (d, J=4.6, 2H), 2.56 (t, J=7.7, 4H), 1.92 (m, 2H), 1.43 (s, 9H). ^{13}C NMR δ 192.9, 155.8,

144.6, 143.1, 79.7, 47.5, 34.2, 30.6, 28.4, 22.5. Anal. Calcd. for: $C_{12}H_{19}NO_3$: C, 63.98; H, 8.50; N, 6.22. Found: C, 63.71; H, 8.51; N, 6.15.

Alcohol (6). Ketone **5** (1.35 g, 6.00 mmol) was dissolved in 2.5:1 THF/MeOH (70 ml) and cooled to 0 °C. $CeCl_3$ (2.69 g, 7.20 mmol) was added, followed by $NaBH_4$ (0.46 g, 12 mmol). After stirring 1 h at 0 °C, the reaction was quenched with NH_4Cl (15 mL), diluted with EtOAc (100 mL), washed with NH_4Cl (2 × 20 mL), brine (20 mL), dried on $MgSO_4$ and concentrated. Chromatography on silica with 20% EtOAc in hexane yielded 1.36 g (100%) of product as a white solid. ^1H NMR δ 5.66 (m, 1H), 4.89 (br, s, 1H), 4.31 (d, $J=5.5$, 1H), 3.38 (m, 1H), 3.13 (m, 1H), 2.31 (m, 4H), 1.88 (m, 2H), 1.43 (s, 9H) ^{13}C NMR δ 156.7, 144.6, 126.4, 79.6, 70.9, 45.3, 32.3, 31.9, 28.4, 23.4. Anal. Calcd for: $C_{12}H_{21}NO_3$: C, 63.41; H, 9.31; N, 6.16. Found: C, 63.63; H, 9.47; N, 6.09.

Ester (7). To a solution of alcohol **6** (12 mg, 0.053 mmol) and pyridine (13.3 μL, 0.165 mmol) in THF (0.1 mL) was added a solution of *t*-butyldimethylsilyloxyacetyl chloride[21] (12 mg, 0.055 mmol) in THF (0.1 mL) dropwise at 0 °C. The reaction was stirred for 0.5 h at rt then diluted with 5 mL Et_2O, washed with 0.5 N HCl (2 × 0.4 mL), $NaHCO_3$ (1 mL), brine (1 mL), dried on $MgSO_4$ and concentrated. Chromatography with 5% EtOAc in hexanes on silica gave 14.5 g (67%) of ester **7** as colorless oil. ^1H NMR δ 5.67 (s, 1H), 5.48 (br, s, 1H), 4.64 (br, s, 1H), 4.24 (s, 2H), 3.43 (m, 1H), 3.33 (m, 1H), 1.87 (m, 2H), 1.45 (s, 9H), 0.90 (s, 9H), 0.08 (s, 6H). ^{13}C NMR δ 171.2, 155.8, 139.9, 128.8, 79.6, 72.8, 61.8, 42.8, 32.4, 32.0, 28.4, 25.9, 25.6, 23.1, -5.4.

α-Hydroxy acid (8). To a solution of diisopropylamine (0.21 mL, 1.5 mmol) in THF (2.0 mL) was added *n*-butyl lithium (2.5 M in hexane, 0.54 mL, 1.3 mmol) at 0 °C. The mixture was stirred for 15 min to generate LDA. Then a mixture of chlorotrimethyl silane (0.46 mL, 3.7 mmol) and pyridine (0.32 mL, 4.0 mmol) in THF (0.8 mL) was added dropwise to the LDA solution at −100 °C. After 5 min, a solution of ester **5** (136 mg, 0.333 mmol) in THF (1 mL) was added dropwise and the reaction was stirred at −100 °C for 25 min then warmed slowly to rt over 1.5 h and heated to 45 °C for 1 h. The reaction was quenched with 1 N HCl (5.0 mL) and the aqueous layer was extracted with Et_2O (2 × 7 mL). The organic layer was dried on $MgSO_4$ and concentrated to give 106 mg (crude yield 78%) yellowish glassy oil. Without further purification, the product was dissolved in 0.8 mL THF. Tetrabutylammonium fluoride (261 mg, 1.00 mmol) in THF (0.5 mL) was added at 0 °C, stirred at 0 °C for 5 min then at rt. for 1 h. The reaction was quenched with 0.5 N HCl (2 mL), extracted with EtOAc (5 mL), dried on $MgSO_4$ and concentrated. Chromatography with 5% methanol in $CHCl_3$ on silica gave 46.2 mg (52%) of α-hydroxy acid **8** as yellowish oil. ^1H NMR (DMSO-d_6) δ 6.81, (br, s, 1H)), 5.31 (br, s, 1H), 3.84 (d, $J=5.8$, 1H) 3.48 (m, 2H), 3.16 (t, $J=8.5$, 1H) 2.64 (m, 1H), 2.27 (m, 1H), 2.12 (m, 1H), 1.70 (m, 2H), 1.58-1.42 (m, 2H), 1.37 (s, 1H). ^{13}C NMR (DMSO-d_6) δ 175.4, 156.0, 144.4, 120.2, 79.7, 78.0, 73.7, 58.1, 47.4, 29.8, 28.9, 24.5, 23.6, 24.5, 23.6, 19.8, 14.1.

Acid (9). Lead tetraacetate (78 mg, 0.17 mmol) in $CHCl_3$ (0.4 mL) was added dropwise to a solution of acid **8** (45.6 mg, 0.16 mmol) in EtOAc (2.2 mL) at 0 °C. The reaction was stirred for 10 min, then quenched with ethylene glycol (0.6 mL), diluted with EtOAc (20 mL), washed with H_2O (4 × 2 mL) and brine (2 mL), dried on Na_2SO_4, and concentrated to give 38 mg (100% crude yield) of aldehyde as yellow oil. The product was dissolved in acetone (4.8 mL) and cooled to 0 °C. Jones reagent (2.7 M H_2SO_4, 2.7 M CrO_3; 0.12 mL, 0.32 mmol) was added dropwise. The reaction was stirred at 0 °C for 0.5 h, quenched with isopropyl alcohol (0.5 mL), and stirred for 10 min. The precipitate was filtered out, and the solvent was evaporated. The residue was extracted with EtOAc (3 × 5 mL), washed H_2O (1.5 mL) and brine (1.5 mL), dried

on Na_2SO_4, and concentrated. Chromatography on silica with 40% EtOAc and 0.1 acetic acid in hexane gave 12.5 mg (31%) of acid **9** as a white solid. ^1H NMR (DMSO-D$_6$) δ 12.16 (br, s, 1H), 6.93 (t, J=5.4, 1H), 5.37 (s, 1H), 3.50 (m, 2H), 3.16 (t, J=7.3, 1H), 2.29 (m, 1H), 2.22 (m, 1H), 1.80 (m, 3H), 1.55 (m, 1H), 1.37 (s, 9H). ^{13}C NMR (DMSO-D$_6$) δ 175.3, 156.1, 142.9, 120.8, 78.1, 49.5, 30.1, 29.2, 28.8, 25.0. Anal. Calcd for: $C_{13}H_{21}NO_4$: C, 61.16; H, 8.29; N, 5.49. Found: C, 61.11; H, 8.25; N, 5.48.

Amide (10): 1-Hydroxybenzotriazole (HOBt, 191.6 mg, 1.25 mmol), *N*-[(1H-benzotriazol-1-yl)(dimethylamino)methylene]-*N*-methylmethanaminiun hexafluorophosphate *N*-oxide (HBTU, 473.8 mg, 1.25 mmol), DIEA (3225/5 mg. 2/5 mmol) and acid **7** (119.6 mg, 0.5 mmol) were dissolved in DMF (25 mL), 4-Hydroxyproline methyl ester hydrochloride salt (224.5, 1.25 mmol) was added. The reaction mixture was stirred at rt for 1 h, then diluted with EtOAc (75 mL), washed with H_2O (3 × 25 mL), $NaHCO_3$ (25 mL), brine (25 mL), dried on $MgSO_4$ and concentrated. Chromatography with 50% EtOAc in hexanes yielded 110 mg of syrup.

Amine (11): Amide **10** (110 mg, 0.302 mmol) and triethylsilane (87.79mg, 0.755 mmol) were dissolved in 25% TFA in DCM and stirred for 0.5 h at rt. Solvent was removed by evaporation. Remaining TFA and triethyl silane was removed by vacuum. Without further purification, the residue was dissolved in 2 mL DCM, tert-butyldimethylsilyl chloride (91 mg, 0.604 mmol) and imidazole (82 mg, 1.208 mmol) was added. The reaction mixture was stirred at rt. For 4 h then dulited with EtOAc, washed with NaHCO3 (2 × 7 mL), H2O (7 mL), dried on $MgSO_4$ and concentrated. Chromatography on silica gel with 15% MeOH in chloroform gave 81 mg (67.7%) colorless oil.

Acid (12): To a solution of amine **11** (80 mg, 0.2 mmol) in THF (1.2 mL) was slowly added a solution of potassium hydroxide in 1:2 MeOH: H2O (0.6 mL) at -10 °C. After stirring for 1 h at 0 °C, the reaction was diluted with 5 mL THF, acidified with 1 N HCl (0.21 mL), dried over $MgSO_4$ and concentrated. Chromatography on silica gel with 15% MeOH in CHCl$_3$ yielded 50 mg (yield 65.3%) of colorless oil.

References

1. Kramer RZ, Bella J, Mayville P, Brodsky B, Berman HM: **Sequence dependent conformational variations of collagen triple-helical structure**. *Nat. Struct. Biol.* 1999, 6:454-457.
2. Bansal M, Ramakrishnan C, Ramachandran GN: In *Proc. Indian Acad. Sci.*: 1975:152-164.
3. Ramachandran GN, Ramakrishnan C: *Biochemistry of Collagen*. N.Y., London: Plenum Press; 1976.
4. Bruckner P, Eikenberry EF, Prockop DJ: **Formation of the triple helix of type I procollagen in cellulo. A kinetic model based on cis-trans isomerization of peptide bonds**. *Eur J Biochem* 1981, 118:607-613.
5. Sarkar SK, Young PE, Sullivan CE, Torchia DA: **Detection of cis and trans X-Pro peptide bonds in proteins by 13C NMR: application to collagen**. *Proc Natl Acad Sci U S A* 1984, 81:4800-4803.
6. Dolz R, Engel J, Kuhn K: **Folding of collagen IV**. *Eur J Biochem* 1988, 178:357-366.
7. Buevich AV, Dai QH, Liu X, Brodsky B, Baum J: **Site-specific NMR monitoring of cis-trans isomerization in the folding of the proline-rich collagen triple helix**. *Biochemistry* 2000, 39:4299-4308.

8. Xu Y, Hyde T, Wang X, Bhate M, Brodsky B, Baum J: **NMR and CD spectroscopy show that imino acid restriction of the unfolded state leads to efficient folding.** *Biochemistry* 2003, **42**:8696-8703.

9. Doege KJ, Fessler JH: *J. Biol. Chem.* 1986, **261**:8924-8935.

10. Eyles SJ, Gierasch LM: **Multiple roles of prolyl residues in structure and folding.** *J Mol Biol* 2000, **301**:737-747.

11. Lee CH, Singla A, Lee YM: *Int. J. Pharmaceutics* 2001, **221**:1-22.

12. Friess W: *Eur. J. Pharm. Biopharm.* 1998, **45**:113-136.

13. Sakikabara S, Inouye K, Shudo K, Kishida Y, Kobayashi Y, Prockop DJ: *Biochim Biophys Acta* 1973, **303**:198-202.

14. Holmgren SK, Bretscher LE, Taylor KM, Raines RT: **A hyperstable collagen mimic.** *Chem Biol* 1999, **6**:63-70.

15. Li C, McCarthy JB, Furcht LT, Fields GB: **An all-D amino acid peptide model of alpha1(IV)531-543 from type IV collagen binds the alpha3beta1 integrin and mediates tumor cell adhesion, spreading, and motility.** *Biochemistry* 1997, **36**:15404-15410.

16. Wang XJ, Hart SA, Xu B, Mason MD, Goodell JR, Etzkorn FA: **Serine-cis-proline and Serine-trans-proline Isosteres: Stereoselective Synthesis of (Z)- and (E)-Alkene Mimics by Still-Wittig and Ireland-Claisen Rearrangements.** *J. Org. Chem.* 2003, **68**:2343-2349.

17. Morvan FO, Baroukh B, Ledoux D, Caruelle JP, Barritault D, Godeau G, Saffar JL: **An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters.** *Am J Pathol* 2004, **164**:739-746.

18. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J: **Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis.** *Rheumatology (Oxford)* 2002, **41**:78-87.

19. Hopkins TE, Pawlow JH, Koren DL, Deters KS, Solivan SM, Davis JA, Gómez FJ, Wagener KB: **Chiral Polyolefins Bearing Amino Acids.** *Macromolecules* 2001, **34**:7920-7922.

20. Niel G, Roux F, Maisonnasse Y, Maugras I, Poncet J, Jouin P: **Substrate-controlled Croylboration from N-(tert-Butoxycarbonyl)amino Aldehydes.** *J. Chem. Soc. Perkin Trans. 1* 1994, **10**:1275-1280.

21. Bischofberger N, Waldmann H, Saito T, Simon ES, Lees W, Bednarski MD, Whitesides GM: **Synthesis of Analogues of 1,3-Dihydroxyacetone Phosphate and Glyceraldehyde 3-Phosphate for Use in Studies of Fructose-1,6-diphosphate Aldolase.** *J. Org. Chem.* 1988, **53**:3457-3465.